Standard Alzheimer’s Treatments Seen to Prevent Effects of TauRx’s Tau Inhibitor

Standard Alzheimer’s Treatments Seen to Prevent Effects of TauRx’s Tau Inhibitor
TauRx Therapeutics’ experimental Alzheimer’s disease treatment LMTX may slow cognitive decline in patients at doses as low as 4 mg — but only when used without other Alzheimer’s drugs — a recent report shows. The findings support data from an earlier Phase 3 trial, which also studied much higher doses of the drug, and have opened up for a study comparing the low dose to a placebo, the company reported. The study reporting the insights, “Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer’s Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial,” was published online in the Journal of Alzheimer's Disease. In 2016, TauRx reported results from its initial Phase 3 trial (NCT01689246) in the journal The Lancet. The study had explored the effect of two high doses twice daily, 75 mg and 125 mg, of LMTX in patients with mild to moderate Alzheimer's disease. Since the drug is known to cause urine and feces to take on an abnormal color, researchers used a 4 mg dose twice a day as a control, instead of using a placebo. Patients in the trial were allowed to take other Alzheimer’s drugs, such as cholinesterase inhibitors or memantine. The analysis revealed no statistically significant benefit of the higher doses when taken together with other medications, but when resea
Subscribe or to access all post and page content.


  1. Zachary Yim says:

    Surprising to see the effect of Tau dis-aggregation can result in higher glucose uptake. Does it mean insulin resistance is downstream of Tau pathology? Other animal models seems to show the opposite situation. Does it also mean this treatment would eliminate the need for intranasal insulin?

    • Ari Magill says:

      Seems to me like intranasal insulin would bolster the effect, a combined approach might be best. I’m very curious how Acetylcholinesterase inhibitors negate the beneficial effect of tau aggregation inhibitors

Leave a Comment

Your email address will not be published. Required fields are marked *